Transcript Highlights:

• A continued challenge is that there are multiple cannabinoid markets in California.
• More recently, a market has emerged for hemp-derived cannabinoids.
• And within the unlicensed cannabinoid markets, products may be sold to kids or contain harmful ingredients
• There have been discovered such issues as cannabinoid hyperemesis syndrome.
• There's other intoxicating cannabinoids that may have more harmful risk, and it's doing all of those

Summary: The joint informational hearing focused on the Department of Cannabis Control’s report on the condition and health of California’s cannabis industry. Department staff reviewed the evolution of state cannabis law, the creation of the current regulatory framework, licensing and compliance efforts, and enforcement against illicit cannabis and hemp-derived intoxicating cannabinoids. The department said the licensed market has grown in production and retail units sold, while active licenses and retail sales value have declined, and that the illicit market remains a major competitive factor. The department also highlighted consumer education efforts, product testing and recalls, and coordination through the state enforcement task force and other agencies. The department’s economist said the data show continued growth in licensed production and a rising share of consumption through the licensed market, but falling wholesale and retail prices have reduced overall industry value. He identified major headwinds as taxes and fees, illicit-market competition, local prohibitions that limit retail access, regulatory costs, and broader business pressures, while noting opportunities in product innovation and possible hemp-market changes. Committee members pressed the department on enforcement, public health concerns, equity ownership and employment, delays in grant administration, pesticide testing, and whether the legal market is truly viable for small businesses and farmers. Several members argued that stronger enforcement and lower costs are needed, while one member raised concerns about cannabis-related health harms and said the hearing focused too narrowly on supply-side issues. Public commenters from industry groups and advocacy organizations largely echoed concerns about high taxes, regulatory burdens, limited retail access, and the size of the illicit market. Many urged the Legislature not to let the excise tax rise from 15% to 19% and called for tax relief, compliance reform, more enforcement, and broader retail access. Some speakers said the report was too optimistic and did not reflect business failures, debt, and closures, while others emphasized the need to protect small farmers, address wildfire insurance, and support equity businesses. No votes or formal actions were taken; the hearing was informational only.

Bills: SB5, SB11, SB12, SB9, SB42, SB15, SB5, SB11, SB12, SCR1

Keywords: hemp regulation, consumable products, cannabinoids, occupational licenses, criminal offenses, SB 11, Texas attorney general, election crimes, election law enforcement, criminal prosecution, Election Code, Government Code Chapter 402, local prosecutors, county attorney, district attorney, grand jury, probable cause reports, state election offenses, voter fraud, election integrity

Bills: SB5, SB11, SB12, SB9, SB42, SB15, SB5, SB11, SB12, SCR1

Keywords: hemp regulation, consumable products, cannabinoids, occupational licenses, criminal offenses, SB 11, Texas attorney general, election crimes, election law enforcement, criminal prosecution, Election Code, Government Code Chapter 402, local prosecutors, county attorney, district attorney, grand jury, probable cause reports, state election offenses, voter fraud, election integrity

Transcript Highlights:

• CBD and CBG will be available because of the molecular makeup of those two cannabinoids show no psychotropic
• I think then we have come to an agreement that under proper medical supervision cannabinoid products
• Okay now I'm going to ask you about synthetic cannabinoids like delta-8 and delta-10.
• The DEA has always maintained that synthetic cannabinoids are illegal, so you've got three federal agencies
• Do you imagine that the cost of the legitimate medical use of THC and cannabinoids will go up because

Bills: SB5, SB11, SB12, SB9, SB42, SB15, SB5, SB11, SB12, SCR1

Keywords: hemp regulation, consumable products, cannabinoids, occupational licenses, criminal offenses, SB 11, Texas attorney general, election crimes, election law enforcement, criminal prosecution, Election Code, Government Code Chapter 402, local prosecutors, county attorney, district attorney, grand jury, probable cause reports, state election offenses, voter fraud, election integrity

Transcript Highlights:

• Would this be called a psychoactive or psychotropic drug or both, or can you clarify?
• So there is a psychoactive component to this, and it would be called psychotropic as well.
• There is a psychoactive component in terms of visual and auditory phenomena.
• So Ibogaine has psychoactive properties and no known medical use.
• You're talking about a psychotropic, whether you're talking about a psychoactive drug or even a psychedelic

Bills: HB 44, HB 2200, HB 1612, HB 2747, HB 2038, HB 3717, HB 1431, HB 3800, HB 3801, HB 3560, HB 3246

Keywords: HB 44, Life of the Mother Act, abortion exceptions, medical emergency, reasonable medical judgment, pregnancy complications, maternal health, life-threatening condition, ectopic pregnancy, miscarriage, spontaneous abortion, fetal survival, Texas abortion law, abortion ban, physician liability, health care provider, disciplinary action, aiding and abetting, emergency abortion, obstetric care

Summary: The meeting of the public health committee focused on the pressing issue of opioid addiction in Texas, with a particular emphasis on House Bill 3717. Chairman Harris detailed the bill's intent to fund a grant program for Ibogaine clinical trials, framing it as a critical response to the ongoing opioid crisis. He shared poignant testimonies highlighting the struggles of families and veterans battling addiction and mental health issues. The conversation underscored the necessity of innovative treatments, like Ibogaine, which showed promising results in studies for reducing symptoms of withdrawal and PTSD.

Transcript Highlights:

• One of the bills would allow the ATCs to outsource non-intoxicating hemp-derived cannabinoids like CBD
• One of the bills would allow the ATCs to outsource non-intoxicating hemp-derived cannabinoids like CBD
• One of the bills would allow the ATCs to outsource non-intoxicating hemp-derived cannabinoids like CBD
• One of the bills would allow the ATCs to outsource non-intoxicating hemp-derived cannabinoids like CBD
• intoxicating hemp derived cannabinoids intoxicating hemp derived cannabinoids like<01:11:44.960>

Keywords: 928, house, all

Summary: The Health and Human Services Oversight Committee met on February 2 and first approved the draft minutes from the prior meeting, with minor corrections to the meeting date and attendance notation. DHHS Associate Commissioner Patricia Tilly then gave a department update, describing the current uncertainty around federal priorities and funding, and provided two substantive reports: progress on the new Hampstead Youth Development Center and an update on the department’s review of an ALS registry proposal. She said the YDC project is underway with tree clearing, fencing, stormwater and site-prep work, and remains on track for completion by June 30, 2026 and operation by August 30, 2026. The center currently has 12 youth, and the new design is intended to provide flexibility for fluctuating census levels. On ALS, Tilly explained that HB 576 had prompted the department to examine whether a registry could be built, but the estimated cost of a HIPAA-compliant system was about $750,000. She said DHHS is reviewing whether existing data sources, such as hospital discharge data and CHIS claims data, could provide useful information, but noted both are incomplete for registry purposes. Committee members discussed whether the Rare Disease Advisory Council, Dartmouth, or existing cancer registry infrastructure could help reduce costs. DHHS said it is neutral and willing to continue exploring alternatives, while members emphasized the value of a registry and the need to consider shared infrastructure and funding. The committee also heard from Jenny Horan of the Alzheimer’s Association, who presented the subcommittee’s report on Alzheimer’s disease and related dementias. She said the subcommittee spent the past year gathering information on dementia care, abuse and exploitation issues, caregiver strain, and available services, and is now moving into a second phase focused on identifying gaps and developing a state plan. Members asked about geriatric psychiatric capacity and long-term care availability; Horan said the state has limited capacity and that the plan will help clarify where needs are greatest. She offered to return for follow-up questions at a later meeting. Finally, Olivia May of DHHS presented the quarterly report on the 12-month postpartum Medicaid coverage extension. She said New Hampshire implemented the extension after federal and state action, and the first claims data are still emerging because of reporting lags. In the initial cohort studied, 95% received some medical services during the extended period, 52.4% received mental health or substance use disorder treatment, 26.7% received preventive visits, and 3.2% received heart or hypertension services. Members asked about return on investment and whether higher federal matching rates are being used appropriately; DHHS said it claims the highest possible match based on eligibility group and will return with more data over time. The committee then heard the annual therapeutic cannabis program report from Michael Holt, who said the program had 1,475 registered patients as of June 30, 2024 and that growth has slowed, with New Hampshire having the lowest per-capita medical cannabis enrollment nationally.

Transcript Highlights:

• The issue that we spotted is in the current hemp law: artificial cannabinoids and synthesized cannabinoids
• have separate meanings, and so an artificial cannabinoid would be a cannabinoid that's created from
• an existing natural cannabinoid, which is converting a CBD cannabinoid that's extracted from hemp into
• And then synthetic cannabinoids is defined as something created from something not pulled from cannabis
• The current hemp law prohibits the use of synthetic and artificially derived cannabinoids in manufactured

Keywords: 910, house, all

Summary: The committee on Consumer Protection and Commerce met on February 5, 2025, and heard testimony on several bills. HB 918, relating to labeling, drew support from the Department of Health, INDA (the nonwoven fabrics industry), and Hawaii Realtors. INDA said the bill aligns with do-not-flush labeling laws in other states but raised a concern about the six-month compliance deadline tied to FIFRA approval. In response to committee questions, witnesses explained that the bill is aimed mainly at disinfecting wipes, that most products are already labeled nationally, and that the proposed timing issue could be addressed by using Oregon’s approach. No vote was taken on the measure during the portion shown. The committee also heard HB 1482, relating to controlled substances. HPD supported the bill, and Aloha Green Holdings and the Department of Health both said they supported the intent but recommended technical amendments. Their testimony focused on clarifying the treatment of Delta-8 THC, distinguishing synthetic or artificially derived cannabinoids from naturally occurring forms, and avoiding confusion in the hemp law. Members asked whether Delta-8 would show up on drug tests; witnesses said it would test positive for THC and would not be distinguished from Delta-9. The bill was then set aside as the committee moved on. HB 981, relating to attorney’s fees, drew opposition from a law firm representing homeowners and associations, which argued the bill would limit access to legal services, favor developers and contractors, and make settlement harder. The witness suggested instead using existing consumer-protection fee-shifting concepts, and committee members explored whether a capped fee award or a broader attorney-fee rule would be more appropriate. The committee then took up HB 807 and HB 336, both relating to condominiums. HB 807 received support from the Green Infrastructure Authority and the Hawaii Bankers Association, while one testifier urged deferral over unresolved questions about commercial PACE financing; the bank association asked for more time to work with HGIA, and the chair indicated decision-making could be deferred to allow that discussion. On HB 336, the Community Associations Institute opposed the bill as removing checks and balances, while the Hawaii Workers Center and others supported it as a step toward clearer enforcement of health and safety issues in condominiums and rental housing.

Transcript Highlights:

• During the second clinic visit, participants also received 5-MeO-DMT, which is another psychoactive compound
• And so when you're on that psychoactive part of the ibogaine administration, you're sort of taking a

Keywords: 1182, all

Summary: The Senate Ad Hoc Committee on Access to Breakthrough Mental Health Therapies met to discuss psychedelic-assisted treatments for serious mental health conditions, with a focus on psilocybin, ibogaine, MDMA, and related compounds. The chair framed the issue as a clinical and access problem for veterans, first responders, and others with PTSD, depression, TBI, addiction, and suicidal ideation, emphasizing that these therapies are intended for supervised medical settings rather than take-home use. Members reviewed research claims and policy trends, including FDA breakthrough therapy designations, state-level psychedelic legislation, and the role of Arizona’s right-to-try law in expanding access once federal approval is in place. Testimony came from Alan Mullen, a retired Army Special Forces veteran, who described his PTSD/TBI history and said ibogaine treatment helped him confront trauma and showed promise in reducing symptoms under strict medical monitoring. Dr. Sue Cisley of Scottsdale Research Institute described ongoing FDA-controlled trials in Arizona, said current medications often fail high-need patients, and urged removal of research barriers and preparation for right-to-try and expanded access. Dan Freiberg of the Professional Firefighters of Arizona said firefighters face chronic exposure to trauma, often rely on alcohol or other coping mechanisms, and need effective alternatives beyond traditional therapy. Dr. Chung Trin discussed late-stage psychedelic trials, the FDA breakthrough pathway, safety oversight, and the need for state readiness when approvals occur. Committee members asked about how the treatments work, whether they require psychotherapy support, safety concerns including suicidality and black-market abuse, patenting and synthetic versus natural versions, and costs compared with ketamine and other treatments. Witnesses said the therapies are administered with extensive screening, monitoring, and integration support, and argued that addiction potential appears low under medical supervision. The discussion ended with interest in sending correspondence to federal officials to support right-to-try cooperation and in continuing the research and policy work; no formal vote or action was taken in the portion provided.

Transcript Highlights:

• responsibilities and improve customer understanding, and adds clarity for enforcement of non-intoxicating cannabinoid
• There's no real health reason to prohibit sublingual application of non-intoxicating cannabinoids, and
• responsibilities and improve customer understanding, and adds clarity for enforcement of non-intoxicating cannabinoid
• Non-intoxicating cannabinoid products. And with that, I will toss it over to Mr. Tabell.
• There's no real health reason to prohibit sublingual application of non-intoxicating cannabinoids, and

Keywords: 1187, senate, all

Transcript Highlights:

• There's clarification about some products like combined cannabinoids, ratio products, and large-format
• clarification about some products<00:02:56.320> like<00:02:56.440> combined<00:02:56.920> cannabinoids
• , products like combined cannabinoids, products like combined cannabinoids, ratio<00:02:58.120>

Keywords: 919, house, all

Summary: Senate File 4401, a cannabis bill, was presented as a broad maintenance package developed through months of work with more than 80 stakeholders, including small businesses, labor, tribal representatives, medical licensees, and the Office of Cannabis Management. The author said it makes a series of technical and policy adjustments, including support for small businesses, hemp QR codes, privacy protections, event coordinator changes, clearer product definitions, investor and timeline changes, and a bridge for hemp businesses to enter cannabis. It also addresses medical cannabis access by renaming medical combination licenses as macro licenses, eliminating the grow-and-sale ratio, correcting canopy estimates, requiring key products to be stocked, and creating a first step toward a medical psilocybin program with a report and federal funding directive. Representative West supported the bill overall but criticized the canopy reduction for medical combination licenses, arguing it changes the rules midstream and could lead to litigation and taxpayer costs. He said the bill helps social equity applicants by allowing more outside investment and described the hemp provisions as a way to save that industry. The author responded that the bill right-sizes a temporary system and reflects stakeholder agreement on needed changes. After discussion, the author again urged a green vote and thanked staff and prior cannabis workers for their help. There were no amendments at the desk, the bill was given a third reading, and the House passed Senate File 4401 by a vote of 92 ayes to 42 nays, with the title agreed to.

Transcript Highlights:

• STARTED COLLECTING LAST SESSION REFLECTS INDIVIDUALS IN THE STATE OF FLORIDA WHO HAVE DIED DUE TO CANNABINOIDS
• AND SYNTHETIC CANNABINOIDS.
• DUE TO THOSE CANNABINOIDS.
• THERE ARE OTHER DEATHS OF INDIVIDUALS WHO HAVE CANNABINOIDS IN THEIR SYSTEM BUT THAT'S NOT THE CAUSE

Keywords: 999, senate, all

Transcript Highlights:

• House Bill 895, Representative Gentry, an act relating to the regulation of psychoactive substances.
• 51:59.840> the<02:52:00.000> regulation<02:52:00.800> of<02:52:01.120> psychoactive
• to the regulation of psychoactive to the regulation of psychoactive substances.<02:52:03.120>

Keywords: 958, all

Summary: The House convened with prayer and the Pledge of Allegiance, then approved the journal, excused absent members, and suspended rules to allow co-sponsorships and vote modifications. The clerk reported Senate Bills 156, 173, and 193 had passed the Senate and requested concurrence. Committee reports were then read, advancing a number of bills on banking and insurance, judiciary, licensing/occupations, and primary/secondary education, including measures on insurance, fraudulent practices, virtual currency kiosks, eminent domain, DUI, legal representation, costs and fees, barbering, fire protection, licensing background checks, dentistry, school reporting, teacher certification, and educator placement. Those favorable reports were treated as first readings and placed on the calendar. The chamber then took up House Bill 307, the “My Kentucky Future Act,” on proactive post-secondary admission. Sponsors explained that the bill would send opt-in letters from public universities to eligible high school juniors, include a common application for the state’s public institutions, and share data with KY Stats to track outcomes. Members asked about scholarships, the target student group, and privacy; the sponsor clarified that participation is voluntary, the letters do not guarantee admission, and the program is meant to streamline college access. House Committee Substitute 2 and House Floor Amendment 2 were adopted, and HB 307 passed 97-0. House Bill 418 on domestic violence was then considered. The sponsor said the bill prioritizes the non-offending parent, requires abusive parents to address violent behavior before unsupervised visitation, and gives courts more tools to consider false abuse allegations and victim advocates’ testimony. House Committee Substitute 1 was adopted, and after brief discussion the bill passed 96-1. House Bill 593 on data centers followed; its sponsor said the measure is intended to support data center development while protecting ratepayers from subsidizing infrastructure risk, requiring companies to bring their own generation, buy power on the open market, or prepay certain costs. After adopting House Committee Substitute 1, the bill passed 90-8. The House also passed House Bill 5 on prison educational programs, with a committee substitute and a floor amendment adding data collection on post-release employment; it passed 99-0. Finally, House Bill 584 on licenses for prescribing or dispensing controlled substances was debated. The sponsor said the bill removes a permanent ban so a physician who has regained licensure may apply for DEA registration, while opponents raised concerns about repeated misconduct and the ability to practice without DEA authority. The transcript cuts off before final disposition on HB 584.

Transcript Highlights:

• updating the warning labels to include cannabis-induced psychosis, chronic psychotic disorder, and cannabinoid
• people, if you use high doses, you risk various significant consequences, including psychosis and cannabinoid
• effects on developing brains, including cannabis use disorder, cannabis-induced psychosis, and cannabinoid
• effects on developing brains, including cannabis use disorder, cannabis-induced psychosis, and cannabinoid
• Harms like cannabis-induced psychosis, cannabinoid hyperemesis syndrome, increased ER visits, worsening

Keywords: 995, all

Summary: The Joint Committee on Cannabis Policy held its fourth hearing, with opening remarks from Senate Chair Adam Gómez and House Chair Dan Donahue emphasizing the committee’s broad agenda, including retail modernization, labor protections, advertising rules, sustainability, and financial resources. Testimony began with public health advocates supporting H.157/S.9 to ban cannabis billboard advertising, arguing that billboards normalize use for youth and are linked to cannabis-related harms such as psychosis, addiction, and cannabinoid hyperemesis syndrome. Witnesses cited research, family stories, and court decisions in Mississippi and Virginia upholding similar restrictions, while committee members questioned the scope of the state’s authority to regulate billboards on private property and the relevance of federal highway funding and federal cannabis law. The committee also heard testimony on H.175, a proposal to allow cannabis drive-through sales. A dispensary operator argued drive-throughs would improve access, especially for disabled customers and veterans, and said security and ID checks could be handled with cameras and staff screening. Committee members pressed him on how employees would assess impairment, whether drive-throughs could increase access for minors, and whether the industry should be treated like alcohol, with the witness responding that staff already refuse service to intoxicated customers and that education, not prohibition, is the better approach. Another bill, H.3982, would apply the bottle deposit law to carbonated hemp- or THC-infused beverages; the sponsor said the measure would standardize recycling requirements for products already sold in dispensaries and other markets, and members asked about container types and recycling compatibility. A major portion of the hearing focused on labor peace agreements, with UFCW representatives, cannabis workers, and Sen. Lydia Edwards supporting S.77/H.161. They said the bill would require cannabis businesses to remain neutral when workers seek to organize, arguing that unions improve safety, wages, benefits, and job stability in an industry they described as underregulated and prone to retaliation. Witnesses cited workplace hazards, wage theft, and the death of a worker at a Holyoke facility as examples of why stronger worker protections are needed. Committee members asked how the proposal differs from existing labor law, whether tying LPAs to licensing and renewal could create legal or administrative problems, and how other states handle similar requirements. No votes or final actions were taken during the hearing.

Bills: SR5, SB5, SB11, SB12, SB25, SB26, SB28, SB35, SB5, SB11, SB12, SB25, SB26, SB28, SB35, SB5, SB11, SB12, SB25, SB26, SB28, SB35, SR5

Keywords: redistricting, Senate procedures, public input, Texas Legislature, amendments, Texas Senate, congressional districts, legislative procedures, legislative transparency, Senate rules, public hearings, committee procedures, hemp regulation, consumable products, cannabinoids, occupational licenses, criminal offenses, SB 11, Texas attorney general, election crimes

Bills: SR5, SB5, SB11, SB12, SB25, SB26, SB28, SB35, SB5, SB11, SB12, SB25, SB26, SB28, SB35, SB5, SB11, SB12, SB25, SB26, SB28, SB35, SR5

Keywords: redistricting, Senate procedures, public input, Texas Legislature, amendments, Texas Senate, congressional districts, legislative procedures, legislative transparency, Senate rules, public hearings, committee procedures, hemp regulation, consumable products, cannabinoids, occupational licenses, criminal offenses, SB 11, Texas attorney general, election crimes

Transcript Highlights:

• does it ban, and it also criminalizes CBN, which is a natural, non-synthetic, non-intoxicant... cannabinoid
• The CBN, I'm not familiar with where the cannabinoids lay, the chemistry behind it.
• are in... intoxicating, and what natural cannabinoids are non-intoxicating.
• a successful model and as other research around the country starts looking into the different cannabinoids
• Synthetic cannabinoids are significant. more potent than grown cannabis and these products are ending

Bills: SCR5, SCR13, SB3, SB6, SB10, SB12, SB13, SB15, SB17, SB18, SB19, SB24, SB35, SB57, SB65, SB112, SB284, SB290, SB388, SB400, SB402, SB412, SB495, SB499, SB502, SB509, SB621, SB706, SB740, SB815, SB842, SB854, SB875, SB893, SB917, SB974, SB1025, SB1061, SB1073, SB1106, SB1268, SB1281, SB1300, SB1362, SB1379, SB1447, SB1451, SB1555, SB1902, SJR36, SJR12, SCR13, SCR25, SCR5, SCR22, SCR12, SCR24, SB495, SB412, SB10, SB18, SB565, SB372, SB842, SB765, SB62, SB19, SB666, SB707, SB888, SB687, SB706, SB847, SB290, SB13, SB1248, SB740, SB14, SB1006, SB504, SB917, SB925, SB388, SB1902, SB1121, SB995, SB857, SB305, SB296, SB284, SB35, SB6, SB815, SB3, SB1281, SB1379, SB1300, SB1497, SB1499, SB1498, SB1451, SB1061, SB15, SB65, SB241, SB304, SB402, SB499, SB621, SB974, SB1023, SB1024, SB1025, SB1106, SB686, SB112, SB371, SB204, SB400, SB609, SB1447, SB670, SB502, SB427, SB850, SB854, SB413, SB1555, SB1362, SB1346, SB1033, SB1220, SB1073, SB810, SB987, SB1539, SB893, SB447, SB875, SB406, SB509, SB985, SB965, SB17, SB1119, SB1505, SB12, SB24, SB57, SB1194, SB1253, SB1215, SB1532, SB1268, SB1302, SB856, SB650, SB583, SB673, SB840, SJR57, SCR8, SB213, SB681, SB1172, SB1252, SB378, SB610, SB918, SB1343, SB608, SB487, SB955, SB957, SB988, SB990, SB1019, SB1021, SB1120, SB251, SB958, SB535, SB761, SB1, SB541, SB315, SB379, SB1018, SB1737, SB266, SB1415

Keywords: SCR 5, Senate Concurrent Resolution 5, Texas School for the Deaf, TSD, Robert Rives, gymnasium naming, building naming, honorary resolution, commemorative resolution, deaf education, hard of hearing, Gallaudet University, alumni hall of fame, football coach, school facility naming, education K-16, State Affairs, Texas Legislature, public school tribute, water rights

Transcript Highlights:

• and courage for states to move forward, but these are we're not talking about naturally derived cannabinoids
• that naturally occurs to the synthetic cannabinoid, but Essentially these are unregulated, untested,
• Opioid, not opioids, got it, but um, cannabinoids, pardon me.
• Um, there are some cannabinoids that are derived from hemp that are the same or similar that are derived
• there's ways that we could see still a legal hemp market without synthetic or intoxicating derived cannabinoids

Transcript Highlights:

• there's been a federal OIG finding for institutionalized individuals that up to 50% receive a psychoactive
• there's been a federal OIG finding for institutionalized individuals that up to 50% receive a psychoactive

Bills: SB20, SB111, SB211, SB218, SB14

Keywords: prior authorization, pharmacy benefits manager, PBM, health insurer, prescription drugs, step therapy, formulary, auto-adjudication, electronic portal, appeals, medical necessity, serious mental illness, mental health, schizophrenia, bipolar disorder, major depression, substance use disorder, addiction treatment, cancer, autoimmune disorder

Transcript Highlights:

• There is a clarification that combined cannabinoids allow up to 400 mg in drinks that are less than 1,000
• MG OF EACH The cannabinoid, or those that are combined, these are actually limits that are set in law
• Importantly, we also allowed the hemp-derived cannabinoids to be used in adult use as they are allowed
• Importantly, we also allowed the hemp-derived cannabinoids to be used in adult use as they are allowed
• Importantly, we also allowed the hemp-derived cannabinoids to be used in adult use as they are allowed

Keywords: 1187, senate, all

Bills: SB 2, SB 3, SB 4, SB 5, SB 6, SB 7, SB 8, SB 9, SB 10, SB 11, SB 12, SB 13, SB 14, SB 15, SB 16, SB 17, SB 18, SB 34

Keywords: flash flood, flood warning, outdoor warning siren, emergency alert, disaster preparedness, flood mitigation, Hill Country floods, Texas Water Development Board, municipalities, counties, local government mandate, public safety, grant program, backup power, weather siren, emergency management, flood-prone area, warning system, redistricting, election